Prostate Cancer

Men with a baseline PSA between 1.5 and 4.0 ng/mL faced a 15-fold increase in prostate cancer over a four-year period as compared with men whose baseline PSA levels were

An interim analysis of the COU-AA-302 trial investigating the use of abiraterone acetate (Zytiga) in chemotherapy-naïve patients with mCRPC showed a trend toward improvement in PFS and OS.

Since the phase III AFFIRM trial of enzalutamide was halted after meeting its endpoint of improved OS, physicians have remained hopeful about its potential as a treatment for prostate cancer.

The novel agent OGX-427 delayed disease progression in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer, according to the preliminary results.

Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.

Preliminary data suggest a promising role for sipuleucel-T as a treatment for African-American men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Abiraterone Acetate's Mechanism of Action

Patients with prostate cancer can expect better sexual function after a robotic-assisted radical prostatectomy (RARP) if they maintain a healthy lifestyle.

In tough economic times when many medical practices have scaled back or even shut down, The Urology Group has flourished.

Spurred by the desire to provide the full spectrum of care to prostate cancer patients, urologists across the country have begun to integrate bone health clinics into their practices.

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses Neoadjuvant Abiraterone Acetate

Marital status is an independent predictor of disease-related mortality and overall mortality in men with prostate cancer.

Dr. Lawrence Fong from University of California, San Francisco, Discusses Immune Response to Sipuleucel-T

The cancer proliferation marker Ki-67 decreased significantly in men who took high-dose vitamin D in the weeks leading up to radical prostatectomy for localized prostate cancer.

Case-based discussion on sequencing prostate cancer therapies for a 72-year-old man with a metastatic adenocarcinoma with small-cell components, a PSA score of 80, and a Gleason score of 10.

Neal D. Shore, MD, Managing Partner, Atlantic Urology Clinics, Director, CPI, Carolina Urologic Research Center, discusses enzalutamide, a well tolerated oral therapy.

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer.

Enzalutamide seems poised to become an exciting addition to the growing list of novel therapies approved for the treatment of prostate cancer.

Oncology specialists who treat patients with mCRPC can look forward to choosing from an expanding array of therapeutic tools, including regimens.

Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.